Study (year) [Ref.] | Country | Patients | Inclusion criteria | Intervention: dose (mg/d) | Number randomized (withdrawals or dropouts) | Follow-up (months) |
---|---|---|---|---|---|---|
Grand I (2002) [26] | USA | HF-PEF and HBP | LVEF >50%; BP >140/90Â mmHg; LV diastolic dysfunction; normal renal function | Canrenone:50 | 17 (NR) | 6 |
ACEI | 17 (NR) | |||||
Mottram (2004) [27] | Australia | HF-PEF and HBP | LVEF >50%; NYHA II; E/A <1 | Spironolactone:25 | 15 (NR) | 6 |
Placebo | 15 (NR) | |||||
Roongsritong (2005) [28] | USA | Elderly with HF-PEF | LVEF >45%; Age:60–85 years; mild diastolic dysfunction | Spironolactone:25 | 15 (1) | 4 |
Placebo | 15 (1) | |||||
Orea-Tejeda (2007) [29] | Mexico | HF-PEF | LVEF >40%; shortening fraction = 28% | Spironolactone:25–50 | 14 (NR) | 13.79 |
Standard therapy | 14 (NR) | |||||
Mak (2009) [30] | Ireland | HF-PEF | LVEF >45%; NYHA IV; BNP ≥100 pg/mL; diastolic dysfunction | Eplerenone:25 | 24 (0) | 12 |
Standard therapy | 20 (2) | |||||
RAAM-PEF trial (2011) [31] | USA | HF-PEF | LVEF >50%; NYHA II or III; BNP ≥100 pg/mL | Eplerenone:25 (titrated to 50) | 23 (0) | 7 |
Placebo | 23 (2) | |||||
Aldo-DHF trial (2013) [16] | Germany and Austria | HFPEF | LVEF >50%; NYHA II or III; Diastolic dysfunction grade ≥ I | Spironolactone:25 | 213 (9) | 11.6 |
Placebo | 209 (13) | |||||
Kurrelmeyer (2014) [32] | USA | Elderly women with HF-PEF | LVEF >50%; NYHA II or III; E/e' > 15; BNP >62 pg/mL | Spironolactone:25 | 24 (0) | 6 |
Placebo | 24 (0) | |||||
TOPCAT trial (2014) [14] | Americas, Russia, and Georgia | HF-PEF | LVEF >45%; control blood pressure; BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL, diastolic dysfunction (grade ≥ I) | Spironolactone:15–45 | 1722 (160) | 39.6 |
Placebo | 1723 (151) | |||||
DiPasquale (2005) [18] | Italy | MI-PEF | LVEF >40%; ST >1Â mm in the peripheral leads and/or >2Â mm in precordial leads | Canrenoate:25 | 341 (33) | 6 |
placebo | 346 (30) | |||||
Kayrak (2010) [19] | Turkey | MI-PEF | LVEF >40%; successfully revascularized patients with AMI | Spironolactone:25 | 71 (16) | 6 |
Standard therapy | 71 (16) | |||||
Kampourides (2012) [17] | Greece | MI-PEF | LVEF >40%; AMI 1Â day to 7Â days | Eplerenone:25 | 210 (9) | 30 |
Standard therapy | 140 (38) | |||||
Vatankulu (2013) [5] | Turkey | MI-PEF | LVEF >40%; successfully revascularized patients with AMI | Spironolactone:25 | 54 (NR) | 6 |
Standard therapy | 56 (NR) | |||||
REMINDER trial (2014) [15] | European countries | MI-PEF | LVEF >40%; successfully revascularized patients with AMI | Eplerenone: 25 (titrated to 50) | 506 (82) | 10.5 |
Placebo | 506 (79) |